Indaptus Therapeutics, Inc. Common Stock INDP

$3.21 +10.69% at last close
Market Cap$427.71 million
P/E Ratio—
Div Yield—
Volume265.0K
52-Week Range $0.92$5.96

Key Stats

Today's Range
$3.03 – $3.29
50-Day Range
$1.13 – $4.22
52-Week Range
$0.92 – $5.96
Volume
265K shs
Average Volume
352K shs
Market Cap
$427.71 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.14%
Days to Cover
1.00

About Indaptus Therapeutics, Inc. Common Stock

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
5
Exchange
XNAS
Listed
2021-08-04

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.